NCT06254274
A Study of RAY1225 in Participants With Type 2 Diabetes
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 16 words Show 5 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Dec 20, 2025 to Jul 20, 2025
- Study completion date changed from estimate of Dec 20, 2025 to Sep 8, 2025
- Secondary endpoints: details revised at 4 of 4 entries
- Site details revised
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 270 to confirmed 210
- Site details revised
- Notable Primary and study completion dates pushed to Dec 20, 2025v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 20, 2024 to Feb 26, 2024
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change From Baseline in Hemoglobin A1c (HbA1c)
Timeframe: Baseline,Week 24
Secondary (4)
Percentage of Participants With HbA1c Target Value of <6.5%
Percentage of Participants With HbA1c Target Value of <7%
Percentage of Participants With HbA1c Target Value of <5.7%
Change From Baseline in Fasting Serum Glucose
Arms and interventions
RAY1225 (cohort 1)Experimental
Participants received dose1 or dose2 RAY1225 administered subcutaneously (SC) once two week for 24 weeks.
Placebo (cohort 1)Placebo comparator
Participants received Placebo administered SC once two weeks for 24 weeks.
RAY1225 (cohort 2)Experimental
Escalating doses of RAY1225 administered subcutaneously (SC) once two week
Placebo (cohort 2)Placebo comparator
Participants received Placebo administered SC once two week
Drugs: RAY1225, Placebo
Sites
1 site in 1 country
- Peking University People's HospitalBeijingcun, Hebei, China